

**WEDNESDAY 3<sup>rd</sup> SEPTEMBER 2014 COMMENCING 10.30 AM**  
**AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN**

**AGENDA**

- |    |                                    |                  |
|----|------------------------------------|------------------|
| 1. | <b>Welcome and introduction</b>    | <b>Enclosure</b> |
| 2. | <b>Apologies</b>                   |                  |
| 3. | <b>Declarations of interest</b>    |                  |
| 4. | <b>Minutes of previous meeting</b> | 1/AWMSG/0914     |

***To protect commercial confidentiality, the first appraisal will be conducted in private.***

- |    |   |                            |
|----|---|----------------------------|
| 5. | <b>Appraisal 1 - Full Submission (WPAS)</b><br><b>Dolutegravir (Tivicay<sup>®</sup>)</b> in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age | 2/AWMSG/0914<br>Appendices |
|----|---|----------------------------|

***The meeting will now open to the public (approx 11.15am)***

- |     |  |                            |
|-----|--|----------------------------|
| 6.  | <b>Chairman's report (verbal update)</b>   |                            |
| 7.  | <b>National Prescribing Indicators 2013–2014: Analysis of Prescribing Data to March 2014</b>   | 3/AWMSG/0914               |
| 8.  | <b>Appraisal 2 - Full Submission</b><br><b>Paclitaxel albumin-bound nanoparticles (Abraxane<sup>®</sup>)</b> in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas   | 4/AWMSG/0914<br>Appendices |
| 9.  | <b>Appraisal 3 - Full Submission</b><br><b>Vandetanib (Caprelsa<sup>®</sup>)</b> for the treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. For patients in whom rearranged during transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision | 5/AWMSG/0914<br>Appendices |
| 10. | <b>Role of Oral Anticoagulants</b>   | 6/AWMSG/0914               |

- |  |                            |
|--|----------------------------|
| 11. <b>Feedback from AWPAG Meeting 25<sup>th</sup> June 2014</b>   | 7/AWMSG/0914               |
| 12. <b>Appraisal 4 - Full Submission</b><br><b>Pomalidomide (Imnovid<sup>®</sup>)</b> in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy | 8/AWMSG/0914<br>Appendices |
| 13. <b>Appraisal 5 - Full Submission</b><br><b>Fampridine (Fampyra<sup>®</sup>)</b> for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7)  | 9/AWMSG/0914<br>Appendices |

**Date of next meeting:**

**Wednesday 8<sup>th</sup> October, Cardiff Metropolitan University, Llandaff Campus**